Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.25
Bid: 3.20
Ask: 3.30
Change: 0.00 (0.00%)
Spread: 0.10 (3.125%)
Open: 3.25
High: 3.25
Low: 3.25
Prev. Close: 3.25
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: M&C Saatchi pulls Next Fifteen deal support

Fri, 17th Jun 2022 10:46

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Directa Plus PLC, up 10% at 107.00 pence, 12-month range 95.1p-178p. Sees an acceleration in trading in the last two months since the first quarter of the year. The graphene-based product supplier says that revenue from the start of the year to the end of May was approximately 44% ahead of the same period the previous year at EUR4.6 million. Directa Plus says this was driven by growth in all its commercial verticals, with sales in line with expectations.

----------

Bidstack Group PLC, up 6.4% at 2.40p, 12-month range 1.6p-6.15p. The in-game advertising platform hires David Reeves as chair designate to succeed Donald Stewart on September 1. The company says Reeves will serve as a non-executive director in the meantime. Stewart will move to a non-executive role and serve on the audit and remuneration Committees on Reeves' becoming the chair. Reeves has over 30 years' global experience in senior management roles within multinational companies across the video games industry, having working at Sony and Capcom.

----------

AIM - LOSERS

----------

ValiRx PLC, down 12% at 19.15p, 12-month range 17.3p-63p. The drug development company anticipates extension request to the exclusivity period between itself and TheroemRx Inc regarding the proposed sub-licence for VAL201. An exclusivity period was granted to June 30 to enable TheoremRx to progress its financing round, which the sub-licence of VAL201 depends. Progress on financing remains positive, but ValiRx anticipates that an extension to the exclusivity period will be requested and intends to seek "more formal confirmation" of the progress. "The letter of intent and proposed sub-license therefore remain non-binding and there is no guarantee that this sub-license will be executed or that it will generate material revenues within the expected timeframe or at all," it says.

----------

M&C Saatchi PLC, down 7.3% at 164p, 12-month range 122p-227p. Directors pull support for takeover offer by Next Fifteen Communications Group PLC, while still not supporting a rival offer by AdvancedAdvT Ltd. M&C Saatchi directors "no longer consider the terms of the Next 15 offer to be fair and reasonable solely on the basis of the deterioration in value of Next 15 shares since the announcement date," the London-based advertising agency explains. Since announcing its share-based acquisition offer in May, Next Fifteen shares have fallen by around 30%. M&C Saatchi, however, also warns that it may be prevented from delivering on its own plans as a standalone company. Shares in Next Fifteen fall 1.9% on Friday.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
4 May 2020 16:10

ValiRx Competes GBP1.2 Million Placing To Fund VAL201 Trial Close-Out

ValiRx Competes GBP1.2 Million Placing To Fund VAL201 Trial Close-Out

Read more
4 May 2020 14:26

ValiRx shores up capital position with ?1.17m fundraise

(Sharecast News) - Clinical-stage biotechnology company ValiRx announced a conditional fundraise through the conditional issue of 18,069,467 new ordinary shares on Monday, to raise ?1.17m.

Read more
1 May 2020 14:57

UK EXECUTIVE CHANGE SUMMARY: Immedia Picks COO Penney As Interim CEO

UK EXECUTIVE CHANGE SUMMARY: Immedia Picks COO Penney As Interim CEO

Read more
1 May 2020 14:33

ValiRx signs VAL301 deal with Japanese firm

(Sharecast News) - Clinical-stage biotechnology company ValiRx has signed an agreement with an unnamed global Japanese pharmaceutical company to evaluate its therapeutic, VAL301, in order to contemplate a potential future license for its use in the treatment of endometriosis.

Read more
1 May 2020 14:23

ValiRx Signs Drug Transfer Agreement With Japanese Pharma Firm

ValiRx Signs Drug Transfer Agreement With Japanese Pharma Firm

Read more
1 May 2020 10:42

UK WINNERS & LOSERS SUMMARY: RBS Rises Despite Profit Sinking

UK WINNERS & LOSERS SUMMARY: RBS Rises Despite Profit Sinking

Read more
29 Apr 2020 18:19

ValiRx Confirms JV Talks For Non-Core Intellectual Property

ValiRx Confirms JV Talks For Non-Core Intellectual Property

Read more
14 Apr 2020 14:51

UK EXECUTIVE CHANGE SUMMARY: Harvest Minerals CFO Leaves To Save Cost

UK EXECUTIVE CHANGE SUMMARY: Harvest Minerals CFO Leaves To Save Cost

Read more
7 Apr 2020 16:10

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
1 Apr 2020 13:57

ValiRx raises ?0.2m through placing with new investors

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Wednesday that it has conditionally raised ?0.2m gross through the issue of 5,714,288 new ordinary shares at a post-reorganisation price of 3.5p each, with new investors.

Read more
1 Apr 2020 12:12

ValiRx Raises GBP200,000 To Improve "Extremely Weak" Capital Position

ValiRx Raises GBP200,000 To Improve "Extremely Weak" Capital Position

Read more
30 Mar 2020 16:41

ValiRx "Critically Short" Of Working Capital, In Funding Discussions

ValiRx "Critically Short" Of Working Capital, In Funding Discussions

Read more
10 Mar 2020 11:42

ValiRx Still Faces Going Out Of Business; Proposes New Share Plan

ValiRx Still Faces Going Out Of Business; Proposes New Share Plan

Read more
4 Mar 2020 17:25

ValiRx Investors Seek Removal Of Directors Morris And Vainikka

ValiRx Investors Seek Removal Of Directors Morris And Vainikka

Read more
17 Feb 2020 12:48

ValiRx's Future In Doubt As Investors Say No To Capital Reogranisation

ValiRx's Future In Doubt As Investors Say No To Capital Reogranisation

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.